Neurocrine Biosciences (NBIX) Short Interest Ratio & Short Volume → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free NBIX Stock Alerts $137.83 -3.33 (-2.36%) (As of 03/27/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences Short Interest DataCurrent Short Volume2,480,000 sharesPrevious Short Volume2,180,000 sharesChange Vs. Previous Month+13.76%Dollar Volume Sold Short$344.97 millionShort Interest Ratio / Days to Cover2.9Last Record DateMarch 15, 2024Outstanding Shares99,510,000 sharesPercentage of Shares Shorted2.49%Today's Trading Volume1,174,119 sharesAverage Trading Volume1,002,404 sharesToday's Volume Vs. Average117% Short Selling Neurocrine Biosciences ? Sign up to receive the latest short interest report for Neurocrine Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNBIX Short Interest Over TimeNBIX Days to Cover Over TimeNBIX Percentage of Float Shorted Over Time Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! Neurocrine Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20242,480,000 shares $344.97 million +13.8%N/A2.9 $139.10 2/29/20242,180,000 shares $284.27 million No ChangeN/A2.6 $130.40 2/15/20242,180,000 shares $292.12 million +16.0%N/A2.7 $134.00 1/31/20241,880,000 shares $262.77 million -18.6%N/A2.4 $139.77 1/15/20242,310,000 shares $304.99 million +1.8%N/A3.1 $132.03 12/31/20232,270,000 shares $299.10 million -0.4%N/A3.2 $131.76 Get the Latest News and Ratings for NBIX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. 12/15/20232,280,000 shares $274.10 million +8.1%N/A3.2 $120.22 11/30/20232,110,000 shares $246.00 million -7.5%N/A3.1 $116.59 11/15/20232,280,000 shares $252.42 million +2.2%N/A3.4 $110.71 10/31/20232,230,000 shares $247.40 million +1.8%N/A3.4 $110.94 10/15/20232,190,000 shares $247.12 million +18.4%N/A3.2 $112.84 9/30/20231,850,000 shares $208.13 million -8.4%N/A2.6 $112.50 9/15/20232,020,000 shares $227.15 million No ChangeN/A2.8 $112.45 8/31/20232,020,000 shares $219.96 million +3.6%N/A2.6 $108.89 8/15/20231,950,000 shares $207.32 million -3.9%N/A2.6 $106.32 7/31/20232,030,000 shares $206.84 million -12.9%N/A2.7 $101.89 7/15/20232,330,000 shares $221.61 million -3.7%N/A3.1 $95.11 6/30/20232,420,000 shares $228.21 million -5.1%N/A3.3 $94.30 6/15/20232,550,000 shares $246.97 million -1.9%N/A3.5 $96.85 5/31/20232,600,000 shares $232.78 million -6.8%N/A3.7 $89.53 5/15/20232,790,000 shares $273.84 million +5.7%N/A4 $98.15 4/30/20232,640,000 shares $266.75 million +3.5%N/A3.5 $101.04 4/15/20232,550,000 shares $262.09 million -7.6%N/A3.4 $102.78 3/31/20232,760,000 shares $279.37 million +3.4%N/A3.4 $101.22 3/15/20232,670,000 shares $251.27 million +5.1%N/A3.4 $94.11 2/28/20232,540,000 shares $261.87 million -1.6%N/A3.2 $103.10 2/15/20232,580,000 shares $267.62 million -1.2%N/A3.3 $103.73 1/31/20232,610,000 shares $289.53 million +0.8%2.8%3.2 $110.93 1/15/20232,590,000 shares $282.28 million +15.1%2.8%3.2 $108.99 12/30/20222,250,000 shares $268.74 million +0.5%2.4%2.8 $119.44 12/15/20222,240,000 shares $261.39 million -16.7%2.4%2.7 $116.69 11/30/20222,690,000 shares $341.79 million -5.3%2.9%3.3 $127.06 11/15/20222,840,000 shares $325.95 million +8.0%3.0%3.5 $114.77 10/31/20222,630,000 shares $302.77 million -4.0%2.8%3.3 $115.12 10/15/20222,740,000 shares $296.55 million +3.0%2.9%3.6 $108.23 9/30/20222,660,000 shares $282.52 million +10.4%2.8%3.6 $106.21 9/15/20222,410,000 shares $257.70 million +11.6%2.6%3.4 $106.93 8/31/20222,160,000 shares $226.00 million -21.7%2.3%3 $104.63 8/15/20222,760,000 shares $296.40 million +7.0%3.0%3.7 $107.39 7/31/20222,580,000 shares $242.86 million -0.8%2.8%3.3 $94.13SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. NBIX Short Interest - Frequently Asked Questions What is Neurocrine Biosciences' current short interest? Short interest is the volume of Neurocrine Biosciences shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 2,480,000 shares of NBIX short. Learn More on Neurocrine Biosciences' current short interest. What is a good short interest ratio for Neurocrine Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBIX shares currently have a short interest ratio of 3.0. Learn More on Neurocrine Biosciences's short interest ratio. Which institutional investors are shorting Neurocrine Biosciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neurocrine Biosciences: GTS Securities LLC, Parallax Volatility Advisers L.P., Citadel Advisors LLC, PEAK6 Investments LLC, Concourse Financial Group Securities Inc., and Portman Square Capital LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Neurocrine Biosciences' short interest increasing or decreasing? Neurocrine Biosciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,480,000 shares, an increase of 13.8% from the previous total of 2,180,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Neurocrine Biosciences' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Neurocrine Biosciences: Repligen Co. (9.18%), Exelixis, Inc. (2.80%), Halozyme Therapeutics, Inc. (6.52%), Denali Therapeutics Inc. (7.48%), Adaptive Biotechnologies Co. (6.11%), Biogen Inc. (1.84%), Bio-Techne Co. (3.24%), Qiagen (1.49%), Vaxcyte, Inc. (7.92%), BioNTech SE (1.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Neurocrine Biosciences stock? Short selling NBIX is an investing strategy that aims to generate trading profit from Neurocrine Biosciences as its price is falling. NBIX shares are trading down $3.33 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Neurocrine Biosciences? A short squeeze for Neurocrine Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NBIX, which in turn drives the price of the stock up even further. How often is Neurocrine Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBIX, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: RGEN Short Interest EXEL Short Interest HALO Short Interest DNLI Short Interest ADPT Short Interest BIIB Short Interest TECH Short Interest QGEN Short Interest PCVX Short Interest BNTX Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NBIX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits